Clariness, a global patient recruitment company, is pleased to announce its participation at SCOPE Summit 2024 in Florida from 11-14 February 2024.

This year, Clariness is proud to have its co-founder & CEO, Michael Stadler, actively involved in the conference by not only attending but also chairing the afternoon session of the first ever Diversity, Equity and Inclusion (DE&I) track. The DE&I track is an exciting addition to SCOPE 2024, focusing on crucial discussions improving patient diversity.

During the sessions, Michael Stadler will facilitate engaging conversations among industry leaders, welcoming esteemed representatives from Regeneron, Sanofi and Roche. Together, they will explore strategies and initiatives aimed at increasing trial diversity within clinical trials.

“We are excited to be part of SCOPE 2024 and are particularly honoured to lead discussions on diversity, equity and inclusion in clinical trials. At Clariness, we are committed to driving positive change within the industry, and we look forward to sharing our insights and learning from other thought leaders during this impactful event,” said Michael Stadler, founder and CEO of Clariness.

Clariness is dedicated to fostering an environment that promotes inclusivity and equitable access to clinical trials. The company is enthusiastic about the opportunity SCOPE 2024 presents to connect with industry peers, share knowledge and collectively work towards enhancing the future of clinical research.

Clariness invites conference attendees to visit booth 1129 to learn more about the company’s innovative solutions and how it contributes to advancing clinical research. Engage with the team to gain insights into the latest trends, technologies and strategies that Clariness brings to the forefront of the clinical research domain. For more information, please contact

Want to meet Clariness at SCOPE? Request a meeting here: